SGLT2 Inhibitor-pretreated Macrophage Transplantation Improves Adverse Ventricular Remodeling After Acute Myocardial Infarction.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 Oct 2023
01 Oct 2023
Historique:
received:
01
03
2023
accepted:
24
07
2023
pubmed:
3
8
2023
medline:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Macrophages play an important role in the progression of acute myocardial infarction (AMI). Studies have shown that sodium-dependent glucose transporter 2 inhibitor (SGLT2i) after AMI could increase the proportion of M2 type/M1 macrophages and reduces adverse ventricular remodeling (AVR) post-AMI. This study aimed to investigate whether SGLT2i-pretreated macrophage transplantation could reduce AVR after AMI and the underlying mechanisms. C57BL/6 mice were used to establish an AMI model by ligating the coronary arteries. Dynamic observation of transplanted bone marrow-derived macrophages (BMDMs) was performed using an in vivo imaging system. Cardiac function was assessed using echocardiography. The fibrosis ratio was measured using Masson's trichrome staining. Cardiomyocyte (CM) apoptosis was measured using the TUNEL assay. Macrophage subtypes were measured using flow cytometry. We detected the expression of inflammatory factors in the myocardium and serum using enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction. The in vivo imaging system revealed that transplanted SGLT2i-pretreated BMDMs were present in the infarcted myocardium for 7 days. Flow cytometry revealed that SGLT2i-pretreated BMDMs promoted the conversion of native-derived macrophages to the M2 type. SGLT2i-pretreated BMDMs also reduced inflammatory factors (IL-6, TNFα, and IL-1β) in the infarcted myocardium and serum. At 28 days post-AMI, SGLT2i-pretreated BMDMs increased cardiac function and vascular density, but reduced CM hypertrophy. SGLT2i-pretreated BMDMs could reduce CM apoptosis and fibrotic area ratio. In conclusion, transplanted SGLT2i-pretreated BMDMs were present in the infarcted myocardium for 7 days and improved AVR by reducing inflammation and modulating the conversion of native mice-derived macrophages to M2-type macrophages.
Identifiants
pubmed: 37535964
doi: 10.1097/FJC.0000000000001466
pii: 00005344-990000000-00210
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-297Subventions
Organisme : National Natural Science Foundation of China
ID : 81827808
Organisme : National Natural Science Foundation of China
ID : 81870178
Organisme : National Natural Science Foundation of China
ID : 81800221
Organisme : National Natural Science Foundation of China
ID : 81970443
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: heart disease and Stroke Statistics–2016 update: a report from the American Heart Association. Circulation. 2016;133:447–454.
Fernandez RC, Konate K, Josse E, et al. Therapeutic peptides to treat myocardial ischemia-reperfusion injury. Front Cardiovasc Med. 2022;9:792885.
Ho MY, Wang CY. Role of Irisin in myocardial infarction, heart failure, and cardiac hypertrophy. Cells. 2021;10:2103.
Zhang QJ, He Y, Li Y, et al. Matricellular protein Cilp1 promotes myocardial fibrosis in response to myocardial infarction. Circ Res. 2021;129:1021–1035.
Thackeray JT, Hupe HC, Wang Y, et al. Myocardial inflammation predicts remodeling and neuroinflammation after myocardial infarction. J Am Coll Cardiol. 2018;71:263–275.
Wu X, Reboll MR, Korf-Klingebiel M, et al. Angiogenesis after acute myocardial infarction. Cardiovasc Res. 2021;117:1257–1273.
Liao Z, Chen Y, Duan C, et al. Cardiac telocytes inhibit cardiac microvascular endothelial cell apoptosis through exosomal miRNA-21-5p-targeted cdip1 silencing to improve angiogenesis following myocardial infarction. Theranostics. 2021;11:268–291.
Wang X, Guo Z, Ding Z, et al. Inflammation, autophagy, and apoptosis after myocardial infarction. J Am Heart Assoc. 2018;7:8024.
Frangogiannis NG. Pathophysiology of myocardial infarction. Compr Physiol. 2015;5:1841–1875.
Fan ZG, Xu Y, Chen X, et al. Appropriate dose of Dapagliflozin improves cardiac outcomes by normalizing mitochondrial fission and reducing cardiomyocyte apoptosis after acute myocardial infarction. Drug Des Develop Ther. 2022;16:2017–2030.
Guo R, Morimatsu M, Feng T, et al. Stem cell-derived cell sheet transplantation for heart tissue repair in myocardial infarction. Stem Cell Res Ther. 2020;11:19.
Podaru MN, Fields L, Kainuma S, et al. Reparative macrophage transplantation for myocardial repair: a refinement of bone marrow mononuclear cell-based therapy. Basic Res Cardiol. 2019;114:34.
Yue Y, Huang S, Wang L, et al. M2b macrophages regulate cardiac fibroblast activation and alleviate cardiac fibrosis after reperfusion injury. Circ J. 2020;84:626–635.
Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:73–87.
Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310.
Sicklinger F, Meyer IS, Li X, et al. Basophils balance healing after myocardial infarction via IL-4/IL-13. J Clin Invest. 2021;131:e136778.
Care NRCU, Animals AUOL. Guide for the Care and Use of Laboratory Animals. Washington, DC: US National Academies Press; 2011.
Liao YH, Xia N, Zhou SF, et al. Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol. 2012;59:420–429.
Yang XX, Li YY, Gong G, et al. lncRNA260 siRNA accelerates M2 macrophage polarization and alleviates oxidative stress via inhibiting IL28RA gene alternative splicing. Oxid Med Cell Longev. 2022;2022:1–9.
Lim VGM, Bell RMP, Arjun SP, et al. SGLT2 inhibitor, canagliflozin, attenuates myocardial Infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci. 2019;4:15–26.
Lahnwong S, Palee S, Apaijai N, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovasc Diabetol. 2020;19:91.
Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18:15.
Zhu Y, Yang W, Wang H, et al. Hypoxia-primed monocytes/macrophages enhance postinfarction myocardial repair. Theranostics. 2022;12:307–323.
Ma Y, Mouton AJ, Lindsey ML. Cardiac macrophage biology in the steady-state heart, the aging heart, and following myocardial infarction. Transl Res. 2018;191:15–28.
Kim Y, Nurakhayev S, Nurkesh A, et al. Macrophage polarization in cardiac tissue repair following myocardial infarction. Int J Mol Sci. 2021;22:2715.
Frangogiannis NG, Rosenzweig A. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159–173.
Nucera S, Biziato D, De Palma M. The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Int J Dev Biol. 2011;55:495–503.
Zhao J, Li X, Hu J, et al. Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization. Cardiovasc Res. 2019;115:1205–1216.